Antengene’s First-in-Class CD24 mAb ATG-031 Gets US FDA Approval for Phase I Study
Antengene Corp., Ltd (HKG: 6996) has announced that it has received approval from the US...
BioRay Pharmaceutical’s Zuberitamab Approved by NMPA for CD20 Positive DLBCL Treatment
BioRay Pharmaceutical Co., Ltd has announced that its drug zuberitamab has been approved by the...
WestVac Biopharma Receives FDA Approval for COVID-19 Protein Vaccines Targeting XBB Variants
Chengdu-based WestVac Biopharma Co., Ltd has announced receiving clinical trial approval from the National Medical...
CARSgen Therapeutics Initiates Phase II Study for CT041 in Advanced Gastric Cancer
China-based chimeric antigen receptor (CAR)-T cell specialist CARSgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
National Vaccine & Serum Institute Partners with Corning Life Sciences to Foster Innovation
The National Vaccine & Serum Institute has announced a partnership with Corning Life Sciences, aiming...
CDE Lists Three Home-Grown Drugs for Priority Review, Including Myopia Treatment
The Center for Drug Evaluation (CDE) website has indicated that three home-grown drugs are on...
Grand Pharmaceutical’s Novasight Hybrid System Receives Marketing Approval in China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Novasight Hybrid System, a...
HitGen Inc. Enters Research Agreement with ARase Therapeutics to Discover Oncology Inhibitors
China-based HitGen Inc. (SHA: 688222) has announced a research agreement with ARase Therapeutics, Inc. Under...
BeiGene and The Max Foundation Collaborate to Expand Access to Brukinsa for CLL Patients
China-based biotech BeiGene (NASDAQ: BGNE) has formed a collaboration with US-based non-profit organization The Max...
Huadong Medicine’s HDM1002 Receives NMPA Approval for Type 2 Diabetes Clinical Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving clinical trial approval from the...
Everest Medicines Completes Patient Enrollment in Etrasimod Phase III UC Trial
Everest Medicines (HKG: 1952), a China-based biopharmaceutical company, has declared the successful completion of patient...
HuidaGene Secures US Patent for High-Efficiency Cas12Max DNA Editing System
HuidaGene Therapeutics, a China-based biotechnology company, has announced the receipt of patent protection from the...
Jiangsu Hengrui’s SHR0302 Secures Clinical Trial Approval for GVHD Treatment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced the receipt of...
Sanofi’s VaxigripTetra Expands Influenza Vaccine Access to All Ages in China
French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its tetravalent influenza virus split vaccine,...
AstraZeneca’s Nirsevimab on Track for Priority Review for RSV Prevention in Infants
The Center for Drug Evaluation (CDE) website in China indicates that AstraZeneca’s (AZ, NASDAQ: AZN)...
Antengene Submits Market Approval Filing for Xpovio in Indonesia for Multiple Myeloma and Lymphoma
Antengene Corp., Ltd (HKG: 6996) has announced a market approval filing in Indonesia for its...
TYK Medicines Receives CDE Approval for CDK7 Inhibitor TY-2699a Clinical Study
Shanghai-based TYK Medicines has announced that it has received approval from the Center for Drug...
Transcenta Holdings’ TST002 Shows Positive Phase I Results for Bone Density in China
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has announced encouraging Phase I clinical study results...
BeiGene’s Tislelizumab Secures First Approvals Outside China Mainland in Macau
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor,...
Yizun Biomedicine’s CNK-UT Cell Therapy Initiates Patient Enrollment for Solid Tumor Trial
Hangzhou-based cell therapy specialist Yizun Biomedicine Co., Ltd has announced the completion of first patient...